Pfizer will soon provide data to U.S. FDA on fourth COVID shot - Bloomberg

Pfizer (PFE -0.8%) will soon have data on the efficacy of a fourth COVID shot that it will submit to the U.S. FDA, Bloomberg reports.
In a television interview, CEO Albert Bourla said he had just reviewed data on a fourth dose as well as a study on a new vaccine formulation that fights against multiple COVID variants.